Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980091 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980182 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980066 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980149 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980092 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980127 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17980069 | 1.00 | DRD3 (0.46) | DRD3DRD2HSD11B1HTR1A | |
| SCHEMBL17979979 | 0.96 | DRD3 (0.45) | DRD3DRD2HTR1A | |
| SCHEMBL17980208 | 0.96 | DRD3 (0.45) | DRD3DRD2HTR1A | |
| SCHEMBL17979982 | 0.96 | DRD3 (0.45) | DRD3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HSD11B1 779/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | DRD3 240/4885DRD2 212/4885HSD11B1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.